User account menu Search Menu Home Investors Novartis Financial Data Novartis SEC Filings Novartis SEC Filings In accordance with US securities regulations, Novartis files reports with the Securities and Exchange Commission. View all of the Novartis filings through EDGAR, the Electronic Data Gathering, Analysis and Retrieval system, on the SEC website. SEC filings (EDGAR) Related Links Alcon files initial Form 20-F registration statement with SEC for proposed spinoff; plans investor days in New York and London Novartis announces FDA and EMA filing acceptances of Beovu® for patients with diabetic macular edema Novartis achieves important regulatory milestone for AMG 334 (erenumab) in migraine prevention with EMA filing acceptance FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101) Novartis Navigate Patients and Caregivers Healthcare Professionals Researchers Job Seekers Journalists Investors Partners Suppliers Topics Clinical Trials COVID-19 Info Center ESG Explore Stories Diseases Locations Companies Sandoz Advanced Accelerator Applications Footer Bottom © 2021 Novartis AG Terms of Use Privacy Contacts Cookie Settings Site Map Novartis Site Directory This site is intended for a global audience